John D Pluenneke from 9026 N Saint Clair Ave, Kansas City, MO 64154, age 66, Phone: 8167417564

view source

view source

view source

Methods And Compositions Relating To Anti-Interleukin-4 Receptor Antibodies
view source
US Patent:

7186809, Mar 6, 2007
Filed:

Dec 19, 2002
Appl. No.:

10/324493
Inventors:

John D. Pluenneke - Parkville MO, US
Assignee:

Immunex Corporation - Thousand Oaks CA
International Classification:

C07K 16/00
C07K 16/24
A61K 39/395
US Classification:

5303892, 5303891, 5303871
Abstract:

Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that bind to IL-4R but do not induce a biological response, molecules that inhibit IL-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of IL-4 to a cell surface IL-4R. Particular antibodies provided herein include human monoclonal antibodies generated by procedures involving immunization of transgenic mice. Such human antibodies may be raised against human IL-4 receptor. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.

Methods And Compositions Relating To Anti-Interleukin-4 Receptor Antibodies
view source
US Patent:

7465450, Dec 16, 2008
Filed:

Oct 27, 2006
Appl. No.:

11/588696
Inventors:

John D. Pluenneke - Parkville MO, US
Assignee:

Immunex Corporation - Thousand Oaks CA
International Classification:

A61K 39/395
A61K 38/17
C12P 21/08
US Classification:

4241431, 424 852, 53038822, 514 12, 435 691
Abstract:

Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that bind to IL-4R but do not induce a biological response, molecules that inhibit IL-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of IL-4 to a cell surface IL-4R. Particular antibodies provided herein include human monoclonal antibodies generated by procedures involving immunization of transgenic mice. Such human antibodies may be raised against human IL-4 receptor. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.

Soluble Tumor Necrosis Factor Receptor Treatment Of Medical Disorders
view source
US Patent:

20010021380, Sep 13, 2001
Filed:

Feb 7, 2001
Appl. No.:

09/778403
Inventors:

John Pluenneke - Kansas City MO, US
International Classification:

A61K039/395
A61K048/00
A61K031/573
US Classification:

424/131100, 514/044000, 514/171000
Abstract:

The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of TNF by administering a TNF inhibitor, such as recombinant TNFR:Fc, and to combination treatments involving the administration of a TNF inhibitor.

Use Of Interleukin-4 Antagonists And Compositions Thereof
view source
US Patent:

20020002132, Jan 3, 2002
Filed:

Feb 15, 2001
Appl. No.:

09/785934
Inventors:

John Pluenneke - Seattle WA, US
International Classification:

A61K038/16
US Classification:

514/012000
Abstract:

Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that bind to IL-4R but do not induce a biological response, molecules that inhibit IL-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of IL-4 to a cell surface IL-4R. Particular antibodies provided herein include human monoclonal antibodies generated by procedures involving immunization of transgenic mice. Such human antibodies may be raised against human IL-4 receptor.

Methods For Treating Autoimmune And Chronic Inflammatory Conditions Using Antagonists Of Cd30 Or Cd30L
view source
US Patent:

20020064527, May 30, 2002
Filed:

Aug 3, 2001
Appl. No.:

09/921667
Inventors:

Kendall Mohler - Poulsbo WA, US
Dauphine Barone - Everett WA, US
Jacques Peschon - Seattle WA, US
Mary Kennedy - Seattle WA, US
John Pluenneke - Parkville MO, US
International Classification:

A61K039/395
A61K038/17
US Classification:

424/144100, 514/012000
Abstract:

The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF inhibitors.

Method For Treating Cancer
view source
US Patent:

20020076409, Jun 20, 2002
Filed:

Jul 11, 2001
Appl. No.:

09/904245
Inventors:

Carl March - Bainbridge Island WA, US
John Pluenneke - Parkville MO, US
Larry O'Neal - Columbia SC, US
International Classification:

A61K039/395
A61K038/17
US Classification:

424/145100, 514/012000
Abstract:

Methods for treating cancer involve administering an interleukin-4 antagonist to a patient diagnosed with cancer. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (IL-4R) such as a soluble human IL-4 receptor, antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that bind to IL-4R but do not induce a biological response, molecules that inhibit IL-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of IL-4 to a cell surface IL-4R. Co-administration of an IL-4 antagonist and an immune stimulatory molecule is also contemplated. Particular antibodies provided herein include human monoclonal antibodies generated by procedures involving immunization of transgenic mice.

Soluble Tumor Necrosis Factor Receptor Treatment Of Medical Disorders
view source
US Patent:

20030148955, Aug 7, 2003
Filed:

Dec 9, 2002
Appl. No.:

10/314618
Inventors:

John Pluenneke - Parkville MO, US
International Classification:

A61K038/17
US Classification:

514/012000
Abstract:

The invention pertains to methods and compositions for reducing resistance to STI 571 in a chronic myelogenous leukemia patient by administering a TNF inhibitor, such as recombinant TNFR:Fc to such patient.

Inhibition Of Fas Signaling
view source
US Patent:

20030170244, Sep 11, 2003
Filed:

Dec 12, 2002
Appl. No.:

10/318772
Inventors:

John Pluenneke - Parkville MO, US
Timothy Connor - Madison WI, US
International Classification:

A61K039/395
A61K038/23
A61K038/18
US Classification:

424/146100, 514/012000
Abstract:

The present invention relates to the general field of treating bone marrow failure and cancer. The invention, in part, utilizes inhibitors of Fas antigen (CD95) induced apoptosis to treat bone marrow failure and to improve cancer therapies.